Literature DB >> 21246516

Risk factors for survival and local recurrence after particle radiotherapy for single small hepatocellular carcinoma.

S Komatsu1, M Murakami, T Fukumoto, Y Hori, Y Hishikawa, Y Ku.   

Abstract

BACKGROUND: Particle radiotherapy is a novel treatment for malignant tumours. The present study aimed to evaluate risk factors for overall survival and local control after particle radiotherapy of single small hepatocellular carcinoma (HCC), and to identify suitable candidates for this treatment.
METHODS: All patients with a single HCC smaller than 5 cm in diameter treated by particle radiotherapy between 2001 and 2008 were identified retrospectively from a prospectively collected database. Clinical outcomes and prognostic factors were analysed.
RESULTS: A total of 150 patients were included. Five-year overall survival and local control rates were 50.9 and 92.3 per cent respectively. Multivariable analysis revealed that several factors, including age and Child-Pugh classification, significantly influenced overall survival. Proximity to the digestive tract and Child-Pugh classification were independent risk factors for local recurrence. Other tumour factors including size, gross classification, previous treatment, macroscopic vascular invasion, and tumour location in relation to the diaphragm and large vessels did not influence local control rate.
CONCLUSION: Particle radiotherapy seems safe and effective, and may be a novel treatment for small HCC. Recurrences are more frequent when the tumour is located close to the gut.
Copyright © 2011 British Journal of Surgery Society Ltd. Published by John Wiley & Sons, Ltd.

Entities:  

Mesh:

Year:  2011        PMID: 21246516     DOI: 10.1002/bjs.7397

Source DB:  PubMed          Journal:  Br J Surg        ISSN: 0007-1323            Impact factor:   6.939


  6 in total

1.  Two-stage treatment with hepatectomy and carbon-ion radiotherapy for multiple hepatic epithelioid hemangioendotheliomas.

Authors:  Shohei Komatsu; Takeshi Iwasaki; Yusuke Demizu; Kazuki Terashima; Osamu Fujii; Atsushi Takebe; Akihiro Toyokawa; Kazuhiro Teramura; Takumi Fukumoto; Yonson Ku; Nobukazu Fuwa
Journal:  World J Gastroenterol       Date:  2014-07-14       Impact factor: 5.742

2.  HURP expression-assisted risk scores identify prognosis distinguishable subgroups in early stage liver cancer.

Authors:  Ming-Ling Chang; Shi-Ming Lin; Chau-Ting Yeh
Journal:  PLoS One       Date:  2011-10-17       Impact factor: 3.240

3.  Respiratory-gated Proton Beam Therapy for Hepatocellular Carcinoma Adjacent to the Gastrointestinal Tract without Fiducial Markers.

Authors:  Miu Mizuhata; Shigeyuki Takamatsu; Satoshi Shibata; Sayuri Bou; Yoshitaka Sato; Mariko Kawamura; Satoko Asahi; Yuji Tameshige; Yoshikazu Maeda; Makoto Sasaki; Tomoyasu Kumano; Satoshi Kobayashi; Kazutaka Yamamoto; Hiroyasu Tamamura; Toshifumi Gabata
Journal:  Cancers (Basel)       Date:  2018-02-21       Impact factor: 6.639

4.  Surgical spacer placement for proton radiotherapy in locally advanced pancreatic body and tail cancers: initial clinical results.

Authors:  Dongha Lee; Shohei Komatsu; Kazuki Terashima; Hirochika Toyama; Yoshiro Matsuo; Daiki Takahashi; Masaki Suga; Naoko Nishimura; Kentaro Tai; Masahiro Kido; Yusuke Demizu; Sunao Tokumaru; Tomoaki Okimoto; Ryohei Sasaki; Takumi Fukumoto
Journal:  Radiat Oncol       Date:  2021-01-06       Impact factor: 3.481

5.  Prognosis and Risk Factors of Recurrence in HBV-Related Small Hepatocellular Carcinoma After Stereotactic Body Radiation Therapy.

Authors:  Yifan Han; Jianxiang Liu; Jiali Pan; Hongyu Chen; Ning Tan; Qian Kang; Yuqing Yang; Xiaoyuan Xu; Wengang Li
Journal:  Front Oncol       Date:  2022-07-25       Impact factor: 5.738

6.  Outcomes of anterior approach major hepatectomy with diaphragmatic resection for single huge right lobe HCC with diaphragmatic invasion.

Authors:  Jinli Zheng; Shu Shen; Li Jiang; Lunan Yan; Jiayin Yang; Bo Li; Tianfu Wen; WenTao Wang; Mingqing Xu
Journal:  Medicine (Baltimore)       Date:  2018-09       Impact factor: 1.817

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.